Features | Partner Sites | Information | LinkXpress
Sign In
Biostrata Ltd on behalf of Thermo
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Preeclampsia Biomarker Detected Very Early In Pregnancy

By Labmedica International staff writers
Posted on 24 Jul 2014
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).
A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as six weeks into the pregnancy.

Preeclampsia, a cardiovascular disorder of late pregnancy, is characterized as a low-renin hypertensive state relative to normotensive pregnancy, and other non-pregnant low-renin hypertensive disorders often exhibit and are occasionally dependent on elevated arginine vasopressin (AVP) secretion.

Scientists at the University of Iowa (Iowa City, IA, USA) measured copeptin levels throughout pregnancy in maternal plasma from preeclamptic and control women. A total of 54 control pregnant, non-preeclamptic women, 50 pregnant, preeclampsia women, and 33 non-pregnant women were included in the study. Maternal plasma copeptin is an inert, stable biomarker of vasopressin secretion with a substantially longer half-life in the blood than vasopressin.

All maternal plasma copeptin concentrations were measured in duplicate using a commercial enzyme-linked immunosorbent assay (ELISA) specific for human copeptin (USCN Life Science, Inc.; Houston, TX, USA). The minimum detectible dose of human copeptin for this assay was 5.4 pg/mL. To examine if renal function or AVP degradation throughout pregnancy affected copeptin concentration, plasma Cystatin C (Sigma-Aldrich, St. Louis, MO, USA) and USCN Life Science’s vasopressinase were measured in duplicate in all samples utilizing commercial ELISA kits.

Maternal plasma copeptin concentration is significantly higher in pregnant women who developed preeclampsia in comparison with control, non-preeclamptic women in the first, second, and third trimesters. In addition, the trimester-specific copeptin concentrations in preeclamptic women are higher than the plasma copeptin concentration of non-pregnant women. The authors concluded that measurement of AVP release in the first few weeks of pregnancy holds great promise as a novel diagnostic tool to predict the development of preeclampsia, and the inhibition of AVP release or action may represent a novel and rational therapeutic approach in preventing and treating preeclampsia.

Justin L. Grobe, PhD, the senior author of the study, said, “We've broken the circle of 'no test, no model, no cure' which has plagued the preeclampsia field for centuries. Suddenly we have identified a hormone that is elevated well ahead of the disorder, and have demonstrated that this hormone can cause the symptoms. It is only a matter of time before we can therapeutically target this system as a preventative or curative intervention.” The study was published on July 7, 2014, in the journal Hypertension.

Related Links:

University of Iowa
USCN Life Science
Sigma- Aldrich


77 ELEKTRONIKA
KARL HECHT GMBH & CO KG
CELLAVISION AB

Channels

Genetic Tests

view channel
Image: Histopathology of a coronary artery with the most common form of obstructive coronary artery disease (atherosclerosis) and marked luminal narrowing (Photo courtesy of Nephron).

Blood Test Influences Clinical Decisions in Coronary Artery Disease

Clinicians need better approaches to evaluating women at midlife and beyond who present to primary care with chest pain and related symptoms such as an individual's current likelihood of having obstructive... Read more

Microbiology

view channel
Image: The VIKIA Malaria Ag Pf/Pan rapid diagnostic test (Photo courtesy of IMACCESS).

Malaria Rapid Diagnostic Test Evaluated At Point-Of-Care

For over a decade, the development of malaria rapid diagnostic tests (RDTs) has enabled reliable biological diagnostic testing in all situations where previously only clinical diagnosis was available.... Read more

Industry News

view channel

Clinical Lab Automation Sector at USD 5.4 Billion and Growing

Lab automation systems sold to clinical laboratories reached USD 5.4 billion in sales in 2014. Shortage of personnel will further drive these purchases, as will a need for new systems, according to a new market research report on the status of lab automation in both clinical and drug-discovery lab segments.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.